Innate Pharma highlights increased lacutamab clinical activity from interim results of Phase 2 TELLOMAK study with updated Olsen criteria
Innate Pharma to present updated interim Phase 2 efficacy results of lacutamab in mycosis fungoides at the international conference on malignant lymphoma
Innate Pharma highlights proprietary tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 congress
SAR'579 / IPH6101 receives FDA Fast Track Designation in the US for the treatment of hematological malignancies
Innate Pharma highlights Phase 1/2 dose escalation safety and preliminary efficacy of Sanofi developed first NK Cell Engager SAR'579 / IPH6101 in R/R AML
Innate Pharma to present IPH6501 preclinical data at the EHA 2023 congress
Innate Pharma Reports First Quarter 2023 Financial Results And Business Update
Innate Pharma announces exclusive license of antibodies to Takeda for celiac disease research program
Innate Pharma reports Full Year 2022 Financial Results and Business Update
Innate Pharma announces HSR clearance regarding expansion of its collaboration with Sanofi on NK cell engagers
